^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Excerpt:
ABBV-221 has similar activity as depatux-m against an EGFR-amplified GBM patient derived xenograft (PDX) model and is highly effective alone and in combination with standard-of-care temozolomide in an EGFRvIII-positive GBM xenograft model.
DOI:
10.1158/1535-7163.MCT-17-0710